GlassScriptPhysician profile
Jamea Campbell
NPI 1053302141
$8,763.49
in general payments reported to CMS, 2019-2025
35 companies · $1,451 in 2025
The $1,451 reported for 2025 was more than what 91% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,510 · 2020: $478 · 2021: $1,083 · 2022: $977 · 2023: $1,356 · 2024: $1,909 · 2025: $1,451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,707 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,707.02 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,515.72 | 2019-2025 | Skyrizi, Rinvoq |
| Novartis Pharmaceuticals Corporation | $824.26 | 2019-2025 | |
| Dermavant Sciences, INC. | $597.27 | 2023-2024 | Vtama |
| Merz North America, INC. | $534.10 | 2019 | |
| Genzyme Corporation | $501.02 | 2019-2025 | |
| Sun Pharmaceutical Industries INC. | $498.74 | 2020-2025 | Ilumya, Absorica Ld, Winlevi |
| Pfizer INC. | $456.29 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $406.18 | 2021-2025 | Dupixent, Libtayo |
| Ucb, INC. | $357.35 | 2021-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $351.54 | 2022-2025 | Sotyktu |
| Amgen INC. | $348.70 | 2023-2025 | Otezla, Otezla |
| Incyte Corporation | $320.17 | 2021-2024 | Opzelura |
| Galderma Laboratories, L.P. | $272.07 | 2019-2025 | Nemluvio, Aklief |
| Mayne Pharma Commercial LLC | $257.16 | 2019-2025 | |
| Lilly USA, LLC | $162.41 | 2019-2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Allergan, INC. | $157.53 | 2019-2022 | |
| Arcutis Biotherapeutics, INC. | $136.77 | 2023-2025 | Zoryve |
| Leo Pharma INC. | $129.16 | 2019-2025 | Anzupgo |
| Convatec INC. | $120.90 | 2024-2025 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $116.51 | 2019-2024 | Cabtreo |
| Organon LLC | $104.33 | 2025 | Vtama, Nexplanon |
| Celgene Corporation | $84.92 | 2019 | |
| Genentech USA, INC. | $84.62 | 2019-2021 | |
| Biofrontera INC. | $61.59 | 2023-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Janssen Biotech, INC. | $58.06 | 2020-2025 | Tremfya |
| Journey Medical Corporation | $54.64 | 2022-2023 | |
| Mission Pharmacal Company | $45.93 | 2019-2020 | |
| Almirall LLC | $44.40 | 2019-2024 | Klisyri |
| Verrica Pharmaceuticals INC. | $38.17 | 2023-2024 | Ycanth |
| Dusa Pharmaceuticals, INC. | $30.28 | 2019 | |
| Revance Therapeutics, INC. | $27.38 | 2025 | Daxxify |
| Aclaris Therapeutics, INC. | $20.57 | 2019 | |
| Dermira, INC. | $16.01 | 2019 | |
| Strata Skin Sciences, INC. | $15.90 | 2025 | Xtrac |
| Helsinn Therapeutics (U.S.), INC. | $12.84 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamea Campbell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.